Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were takin Wegovy ...

Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...

The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...